Article · 4 May 2026
ArticlePublished 17 May 2024
Evidence-Based Approach to Pregnancy-Induced Hypertension Treatment Using Magnesium Sulfate and Nifedipine
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
This study focused to study the efficacy and safety of magnesium sulfate with nifedipine for pregnancy-induced hypertension receiving evidence-based care. 100 pregnancy-induced hypertension individuals who were treated between January 2022 and December 2022 were selected. On the basis of evidence-based care, 54 patients were given magnesium sulfate with nifedipine and were assigned as research group while 46 individuals were treated with magnesium sulfate alone and were regarded as control group. Data on clinical efficacy, systolic and diastolic blood pressure, heart rate and other complications rate like dyspnea, accelerated heart rate, and nausea and vomiting were comparatively analyzed. Similarly, information regarding umbilical artery resistance index, blood viscosity and adverse pregnancy outcomes such as postpartum hemorrhage, placental abruption and cesarean section were collected among the patients for comparison. The data showed an obviously higher overall response rate of treatment in the research group compared with the control group. Besides, the research group exhibited markedly reduced systolic and diastolic blood pressure, heart rate, umbilical artery resistance index and blood viscosity after treatment were low compared with the control group. Moreover, statistically lower incidence rates of complications and adverse pregnancy outcomes were determined in the research group. The above shows that magnesium sulfate with nifedipine has a beneficial effect on improving the curative effect of pregnancy-induced hypertension patients receiving evidence-based care while ensuring the treatment safety, contributing to better blood pressure and heart rate control, inhibited umbilical artery resistance index and blood viscosity, and a reduced risk of adverse pregnancy outcomes, which is worth of clinical promotion.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Indian Journal of Pharmaceutical Sciences.
Article · 21 Apr 2026
In silico molecular docking analysis of bioactive compounds from Kappaphycus alvarezii and Gracilaria debilis against BRCA1 protein
Article · 11 Mar 2026
Trimethoprim and Sulfamethoxazole-Loaded Nanoparticles Coated With Chitosan for Intranasal Delivery to Treat Cerebral Toxoplasmosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalIndian Journal of Pharmaceutical Sciences
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Fei Liu”
- BylineArticles whose byline prints “Yang Xing”